Increased Competition for Big Pharma in Late-Stage Licensing?
Executive Summary
Do in-licensing-focused specialty pharmas spell tougher competition for Big Pharma, traditionally the biggest customer for late-stage product licenses?
You may also be interested in...
Biotechs As In-Licensers
A closer look at the trend in biotech (top tier, and others) and specialty pharma in-licensing of clinical stage products.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.